194 related articles for article (PubMed ID: 27741509)
1. MEK1 is required for the development of NRAS-driven leukemia.
Nowacka JD; Baumgartner C; Pelorosso C; Roth M; Zuber J; Baccarini M
Oncotarget; 2016 Dec; 7(49):80113-80130. PubMed ID: 27741509
[TBL] [Abstract][Full Text] [Related]
2. MEK1 is required for PTEN membrane recruitment, AKT regulation, and the maintenance of peripheral tolerance.
Zmajkovicova K; Jesenberger V; Catalanotti F; Baumgartner C; Reyes G; Baccarini M
Mol Cell; 2013 Apr; 50(1):43-55. PubMed ID: 23453810
[TBL] [Abstract][Full Text] [Related]
3. A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.
Hayes TK; Luo F; Cohen O; Goodale AB; Lee Y; Pantel S; Bagul M; Piccioni F; Root DE; Garraway LA; Meyerson M; Johannessen CM
Cancer Res; 2019 May; 79(9):2352-2366. PubMed ID: 30819666
[TBL] [Abstract][Full Text] [Related]
4. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.
Queralt B; Cuyàs E; Bosch-Barrera J; Massaguer A; de Llorens R; Martin-Castillo B; Brunet J; Salazar R; Menendez JA
Oncotarget; 2016 Dec; 7(50):82185-82199. PubMed ID: 27636997
[TBL] [Abstract][Full Text] [Related]
5. Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation.
Xu J; Haigis KM; Firestone AJ; McNerney ME; Li Q; Davis E; Chen SC; Nakitandwe J; Downing J; Jacks T; Le Beau MM; Shannon K
Cancer Discov; 2013 Sep; 3(9):993-1001. PubMed ID: 23733505
[TBL] [Abstract][Full Text] [Related]
6. Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia.
Blalock WL; Navolanic PM; Steelman LS; Shelton JG; Moye PW; Lee JT; Franklin RA; Mirza A; McMahon M; White MK; McCubrey JA
Leukemia; 2003 Jun; 17(6):1058-67. PubMed ID: 12764369
[TBL] [Abstract][Full Text] [Related]
7. ERK1/2 can feedback-regulate cellular MEK1/2 levels.
Hong SK; Wu PK; Karkhanis M; Park JI
Cell Signal; 2015 Oct; 27(10):1939-48. PubMed ID: 26163823
[TBL] [Abstract][Full Text] [Related]
8. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.
Pomeroy EJ; Lee LA; Lee RDW; Schirm DK; Temiz NA; Ma J; Gruber TA; Diaz-Flores E; Moriarity BS; Downing JR; Shannon KM; Largaespada DA; Eckfeldt CE
Oncogene; 2017 Jun; 36(23):3263-3273. PubMed ID: 27991934
[TBL] [Abstract][Full Text] [Related]
9. Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy.
Yu K; Toral-Barza L; Shi C; Zhang WG; Zask A
Cancer Biol Ther; 2008 Feb; 7(2):307-15. PubMed ID: 18059185
[TBL] [Abstract][Full Text] [Related]
10. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
11. Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.
Lionetti M; Barbieri M; Todoerti K; Agnelli L; Marzorati S; Fabris S; Ciceri G; Galletti S; Milesi G; Manzoni M; Mazzoni M; Greco A; Tonon G; Musto P; Baldini L; Neri A
Oncotarget; 2015 Sep; 6(27):24205-17. PubMed ID: 26090869
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.
Marampon F; Ciccarelli C; Zani BM
Mol Cancer; 2006 Aug; 5():31. PubMed ID: 16899113
[TBL] [Abstract][Full Text] [Related]
13. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors.
Dworakowska D; Wlodek E; Leontiou CA; Igreja S; Cakir M; Teng M; Prodromou N; Góth MI; Grozinsky-Glasberg S; Gueorguiev M; Kola B; Korbonits M; Grossman AB
Endocr Relat Cancer; 2009 Dec; 16(4):1329-38. PubMed ID: 19620247
[TBL] [Abstract][Full Text] [Related]
14. Small GTPase RBJ mediates nuclear entrapment of MEK1/MEK2 in tumor progression.
Chen T; Yang M; Yu Z; Tang S; Wang C; Zhu X; Guo J; Li N; Zhang W; Hou J; Liu H; Han C; Liu Q; Gu Y; Qian C; Wan T; Cui L; Zhu M; Zheng W; Cao X
Cancer Cell; 2014 May; 25(5):682-96. PubMed ID: 24746703
[TBL] [Abstract][Full Text] [Related]
15. RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth in vitro and in vivo.
Gailhouste L; Ezan F; Bessard A; Frémin C; Rageul J; Langouët S; Baffet G
Int J Cancer; 2010 Mar; 126(6):1367-77. PubMed ID: 19816936
[TBL] [Abstract][Full Text] [Related]
16. Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors.
Voisin L; Julien C; Duhamel S; Gopalbhai K; Claveau I; Saba-El-Leil MK; Rodrigue-Gervais IG; Gaboury L; Lamarre D; Basik M; Meloche S
BMC Cancer; 2008 Nov; 8():337. PubMed ID: 19014680
[TBL] [Abstract][Full Text] [Related]
17. Opposite long-term regulation of c-Myc and p27Kip1 through overactivation of Raf-1 and the MEK/ERK module in proliferating human choroidal melanoma cells.
Lefevre G; Calipel A; Mouriaux F; Hecquet C; Malecaze F; Mascarelli F
Oncogene; 2003 Dec; 22(55):8813-22. PubMed ID: 14654778
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-708 emerges as a potential candidate to target undruggable NRAS.
Pang JM; Chien PC; Kao MC; Chiu PY; Chen PX; Hsu YL; Liu C; Liang X; Lin KT
PLoS One; 2023; 18(4):e0284744. PubMed ID: 37083947
[TBL] [Abstract][Full Text] [Related]
19. Differential regulation of mitogen-activated protein/ERK kinase (MEK)1 and MEK2 and activation by a Ras-independent mechanism.
Xu S; Khoo S; Dang A; Witt S; Do V; Zhen E; Schaefer EM; Cobb MH
Mol Endocrinol; 1997 Oct; 11(11):1618-25. PubMed ID: 9328344
[TBL] [Abstract][Full Text] [Related]
20. Nras(G12D/+) promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions.
Wang J; Kong G; Liu Y; Du J; Chang YI; Tey SR; Zhang X; Ranheim EA; Saba-El-Leil MK; Meloche S; Damnernsawad A; Zhang J; Zhang J
Blood; 2013 Jun; 121(26):5203-7. PubMed ID: 23687087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
